Introduction
============

Endocan, previously called endothelial cell-specific molecule-1, was first cloned by Lassalle et al in 1996 from a human umbilical vein endothelial cell complementary DNA library.[@b1-ott-9-6297] It is a 50 kDa dermatan sulfate proteoglycan, and is secreted by activated vascular endothelial cells, including tumor endothelial cells.[@b2-ott-9-6297]--[@b4-ott-9-6297] Endocan can be upregulated by angiogenic factors and inflammatory cytokines, such as tumor necrosis factor-α and interleukin-1β.[@b1-ott-9-6297],[@b2-ott-9-6297] In previous studies, endocan was found to induce tumor formation and to be closely associated with the conversion of dormant tumors into fast-growing angiogenic tumors.[@b5-ott-9-6297],[@b6-ott-9-6297] Recent studies have shown that endocan is overexpressed at the messenger RNA and/or protein levels in various tumor types, including glioblastoma,[@b7-ott-9-6297] pituitary adenoma,[@b8-ott-9-6297],[@b9-ott-9-6297] nonsmall cell lung cancer,[@b10-ott-9-6297] gastric cancer,[@b11-ott-9-6297]--[@b14-ott-9-6297] colorectal cancer,[@b15-ott-9-6297]--[@b17-ott-9-6297] renal cell cancer,[@b2-ott-9-6297],[@b18-ott-9-6297] bladder cancer,[@b19-ott-9-6297] ovarian cancer,[@b20-ott-9-6297] and hepatocellular carcinoma.[@b21-ott-9-6297]--[@b23-ott-9-6297] Most studies also suggested that endocan overexpression was associated with aggressive tumor progression and poor outcomes.[@b7-ott-9-6297],[@b11-ott-9-6297],[@b13-ott-9-6297]--[@b17-ott-9-6297],[@b20-ott-9-6297],[@b21-ott-9-6297],[@b23-ott-9-6297],[@b24-ott-9-6297] However, conflicting results still exist.[@b12-ott-9-6297],[@b19-ott-9-6297],[@b22-ott-9-6297] Therefore, we conducted a meta-analysis of the available studies to investigate the relationship between endocan expression and prognosis of patients with cancer.

Materials and methods
=====================

Search and selection process
----------------------------

A systematic literature search was conducted of the PubMed, Embase, and China National Knowledge Infrastructure databases, covering all relevant studies published up to September 22, 2015, using the following keywords: "endocan" OR "ESM-1" AND "prognosis" OR "survival" OR "outcome" AND "cancer" OR "carcinoma" OR "neoplasm." The reference lists of the relevant publications were also carefully reviewed to obtain additional information.

Inclusion and exclusion criteria
--------------------------------

To be eligible for inclusion, studies had to meet the following criteria: (a) published as a full paper in the English or Chinese literature; (b) investigated the association between endocan expression and cancer prognosis; and (c) included sufficient data for estimating hazard ratio (HR) with 95% confidence interval (CI). The major reasons for exclusion of studies were: (a) overlapping or duplicate data; (b) publication was either an abstract, comment, or review; and (c) without detailed data. The flow diagram for the study is shown in [Figure 1](#f1-ott-9-6297){ref-type="fig"}.

Data extraction and quality assessment
--------------------------------------

Two reviewers (XH and XW) performed the search and identification independently using a standard approach.[@b25-ott-9-6297] The following items were extracted from each eligible publication: first author, year of publication, nationality, ethnicity (Asian or Caucasian), cancer type, quantitative method (enzyme-linked immunosorbent assay or immunohistochemistry), cutoff value, length of follow-up (months), HR with corresponding 95% CI for overall survival (OS) or recurrence-free survival (RFS), and total number of participants. In cases of discrepancy, another investigator (B-HR) was invited to check and discuss the original data until a consensus was reached. Quality assessment for each study included in the final analysis was carried out by the same two reviewers (XH and XW) according to the Newcastle--Ottawa quality assessment scale (NOS).[@b26-ott-9-6297] The Newcastle--Ottawa scores range from 0 to 9, and a score of ≥6 indicated good quality in the present study.

Statistical analysis
--------------------

HR with 95% CI was calculated for the association between endocan expression and cancer prognosis (OS and RFS). When the statistical variables were reported in the text or tables, we obtained them directly. Otherwise, the methods reported by Tierney[@b27-ott-9-6297] were used to calculate data from Kaplan--Meier survival curves. Heterogeneity between studies was checked using the *χ*^2^-based *Q*-test and considered statistically significant at *I*^2^\>50% or *P*\<0.1. The Mantel--Haenszel fixed-effects model was used if there was no significant heterogeneity; otherwise, the Der Simonian and Laird random effects model was utilized.[@b28-ott-9-6297] Subgroup analyses and logistic metaregression analyses were conducted to explore the source of heterogeneity between variables, such as cancer type, ethnicity, quantitative method, sample size, and study quality. Sensitivity analysis was carried out to identify the effect of data from each study on the pooled HRs. Publication bias was determined by Egger's test and Begg's funnel plots.[@b29-ott-9-6297] All statistical tests were conducted with STATA software version 12.0 (STATA Corporation, College Station, TX, USA), and *P*\<0.05 was considered significant.

Results
=======

Study characteristics
---------------------

In total, 262 potentially relevant studies were identified after the initial database searches. After a rough review of the titles and abstracts of all studies, 212 studies were excluded, then, with a systematical review of the full texts, another 34 studies were excluded ([Figure 1](#f1-ott-9-6297){ref-type="fig"}). After further screening, one article was excluded because of insufficient data.[@b10-ott-9-6297] Moreover, one study[@b22-ott-9-6297] included two different survival analyses separately. Therefore, 15 eligible studies of 1,464 patients were finally included in this meta-analysis.[@b7-ott-9-6297],[@b11-ott-9-6297]--[@b17-ott-9-6297],[@b19-ott-9-6297]--[@b24-ott-9-6297]

The main characteristics of the included studies are summarized in [Tables 1](#t1-ott-9-6297){ref-type="table"} and [2](#t2-ott-9-6297){ref-type="table"}. Of the 15 studies, 10 (1,157 patients: 79.0%) were performed in Asia,[@b11-ott-9-6297]--[@b17-ott-9-6297],[@b21-ott-9-6297],[@b23-ott-9-6297],[@b24-ott-9-6297] and the remaining five studies (307 patients: 21.0%) were conducted in Europe and America.[@b7-ott-9-6297],[@b19-ott-9-6297],[@b20-ott-9-6297],[@b22-ott-9-6297] All of these studies were retrospective in design. The malignant neoplasms assessed in these studies were colorectal cancer,[@b15-ott-9-6297]--[@b17-ott-9-6297] gastric cancer,[@b11-ott-9-6297]--[@b14-ott-9-6297] hepatocellular carcinoma,[@b21-ott-9-6297]--[@b23-ott-9-6297] nasopharyngeal carcinoma,[@b24-ott-9-6297] bladder cancer,[@b19-ott-9-6297] ovarian cancer,[@b20-ott-9-6297] and glioblastoma.[@b7-ott-9-6297] Enzyme-linked immunosorbent assay was used in eight studies,[@b7-ott-9-6297],[@b12-ott-9-6297],[@b13-ott-9-6297],[@b15-ott-9-6297],[@b17-ott-9-6297],[@b21-ott-9-6297],[@b22-ott-9-6297] and immunohistochemistry was used in the remaining six studies.[@b11-ott-9-6297],[@b14-ott-9-6297],[@b16-ott-9-6297],[@b19-ott-9-6297],[@b20-ott-9-6297],[@b23-ott-9-6297],[@b24-ott-9-6297]

Meta-analysis
=============

Endocan expression and OS
-------------------------

Fourteen studies with a total of 1,424 patients provided survival results in the form of OS. As the heterogeneity was not statistically significant (*I*^2^=25.80%, *P*=0.176), the fixed-effects model was used to pool HRs. The result revealed that high endocan expression predicts poor OS in various carcinomas, with a pooled HR of 2.48 (95% CI: 2.12--2.90, *P*\<0.001) ([Figure 2](#f2-ott-9-6297){ref-type="fig"}).

To determine the prognostic role of endocan in different cancers, studies were divided into subgroups by cancer types. The results indicated that high endocan expression was an unfavorable prognostic indicator in both gastrointestinal (HR: 2.27, 95% CI: 1.77--2.91, *P*\<0.001) and hepatocellular (HR: 2.61, 95% CI: 1.96--3.48, *P*\<0.001) carcinoma ([Figure 3](#f3-ott-9-6297){ref-type="fig"}).

Subgroup analyses by ethnicity revealed that endocan was a negative predictor of OS for both Asian (HR: 2.56, 95% CI: 2.11--3.11, *P*\<0.001) and Caucasian (HR: 1.99, 95% CI: 1.22--3.26, *P*=0.006) populations. When considering differences in sample type, high endocan level was a poor prognostic marker for sera (HR: 2.08, 95% CI: 1.61--2.70, *P*\<0.001) and tissue (HR: 2.74, 95% CI: 2.25--3.34, *P*\<0.001). In addition, subgroup analyses showed that an elevated endocan level predicted poor prognosis, regardless of sample size and the study quality ([Table 3](#t3-ott-9-6297){ref-type="table"}).

### Endocan expression and RFS

Three studies[@b16-ott-9-6297],[@b19-ott-9-6297],[@b22-ott-9-6297] were used for RFS analysis with a fixed-effects model (*I*^2^=0.00%, *P*=0.958). Our results indicated that elevated endocan predicted a worse outcome for RFS, with a combined HR of 2.08 (95% CI: 1.40--3.09, *P*\<0.001). Subgroup analysis, metaregression analysis, and sensitivity analysis were not applicable because of the limited number of studies.

Sensitivity analysis
--------------------

We adopted the "leave-one-out" scheme (ie, analysis is conducted using all studies but one) to explore the influence of individual studies on the pooled HRs. The results showed that the pooled HRs were not materially altered, which suggested that no individual study significantly affected the pooled results ([Figure 4](#f4-ott-9-6297){ref-type="fig"}).

Publication bias
----------------

Begg's funnel plot and the Egger's linear regression test were conducted to evaluate the publication bias of the literature. In the pooled analyses of OS and RFS, the Egger's test *P*-values were 0.466 and 0.372, respectively, as shown by symmetric funnel plots ([Figure 5](#f5-ott-9-6297){ref-type="fig"}). Therefore, no evidence of publication bias was noted.

Discussion
==========

Endocan is a soluble dermatan sulfate (DS) proteoglycan, which is secreted by the vascular endothelium and freely circulates in the bloodstream.[@b1-ott-9-6297] Accumulating evidence shows that endocan is related to the regulation of major processes such as cell adhesion, inflammatory disorders, and tumor progression.[@b30-ott-9-6297]--[@b32-ott-9-6297] Inflammatory cytokines, such as tumor necrosis factor-α and interleukin-1, strongly increase the expression and secretion of endocan.[@b1-ott-9-6297],[@b4-ott-9-6297] Endocan also plays vital roles during angiogenesis.[@b33-ott-9-6297] The study by Shin et al[@b34-ott-9-6297] showed that endocan level is increased in endothelial cells treated with vascular endothelial growth factor-A, and that its expression can induce tumor formation. Moreover, treatment of cultured endothelial cells with anti-angiogenic drugs or multityrosine kinase inhibitors can abolish the vascular endothelial growth factor-induced secretion of endocan.[@b35-ott-9-6297] Furthermore, Béchard et al reported a possible feedback mechanism in which tumor epithelial cells secrete growth factors that stimulate endothelial cell proliferation and endocan secretion, then endocan further stimulates tumor cell proliferation and secretion of growth factors and also promotes the proliferation of blood vessels.[@b3-ott-9-6297] Based on these results, it would be of great interest to use endocan expression as a biomarker for the screening of patients susceptible to angiogenesis-targeted therapies and to explore the prognostic value of endocan in various types of cancer.[@b7-ott-9-6297],[@b11-ott-9-6297]--[@b17-ott-9-6297],[@b19-ott-9-6297]--[@b24-ott-9-6297],[@b36-ott-9-6297] However, the results remain controversial for many conditions. The aim of the current study was therefore to evaluate the prognostic value of endocan. To the best of our knowledge, this is the first meta-analysis to evaluate the correlation between endocan overexpression and survival in various cancers.

Meta-analysis is a useful tool to detect effects that may be missed by individual studies.[@b37-ott-9-6297] In the current meta-analysis, we combined 15 publications on 1,464 patients to yield statistics, indicating a statistically significant role of endocan in cancers. Combined HRs suggested that elevated endocan significantly predicts poor OS (HR: 2.48, 95% CI: 2.12--2.90, *P*\<0.001) and RFS (HR: 2.08, 95% CI: 1.40--3.09, *P*\<0.001) in patients with cancer. In addition, the significance of this association was not changed in a sensitivity analysis that removed individual studies. Subgroup analyses showed that the trend toward worse OS with higher endocan level was present in both Asian and Caucasian patients. We performed subgroup analyses based on sample type, and found that patients with low endocan level had better OS compared with those with elevated endocan level, regardless of the sample type. Subgroup analysis stratified by sample size (ie, large or small) and study quality (ie, high or low) also revealed that endocan had a negative effect on OS.

To understand our findings better, some limitations should be considered. First, this meta-analysis was limited to articles published in English and Chinese and could not include studies that were not published because of negative or useless results. Second, our meta-analysis data did not include information on tumor stage, treatment, age, or physical condition, which might result in confounding bias. Third, immunohistochemistry was used as the detecting method in six studies, but it is a relatively complicated technique with many steps and is observer dependent. Fourth, some survival data were not presented directly, so we had to extract HR from survival curves in some enrolled studies,[@b7-ott-9-6297],[@b19-ott-9-6297] and these HRs and 95% CIs might be less reliable than those given directly by the authors. Fifth, the applied methods for detecting endocan expression and the cutoff values were different in different studies, which could cause heterogeneity between the enrolled studies.

In conclusion, despite the limitations of the present study and heterogeneity across the included studies, our meta-analysis suggests that high endocan expression is negatively associated with prognosis of cancer. Future larger scale prospective and standard investigations should be conducted to confirm our results.
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![Meta-analysis (forest plot) of the evaluable studies assessing endocan expression and OS, stratified by cancer type.\
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![Sensitivity analysis for OS: effect of individual studies on pooled HRs for patients with cancer.\
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![Begg's funnel plot of endocan expression and OS in patients with tumors.\
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###### 

Main characteristics of studies included in the meta-analysis

  Authors                            Publication year   Case nationality             Dominant ethnicity   Sample size   Mean age   Malignant disease                   Survival analysis   Source of HR   Follow-up months   NOS score
  ---------------------------------- ------------------ ---------------------------- -------------------- ------------- ---------- ----------------------------------- ------------------- -------------- ------------------ -----------
  Jiang et al[@b15-ott-9-6297]       2015               People's Republic of China   Asian                89            NA         Colorectal cancer                   OS                  Reported       NA                 7
  Zhao et al[@b11-ott-9-6297]        2014               People's Republic of China   Asian                255           NA         Gastric cancer                      OS                  Reported       300                7
  Sun et al[@b12-ott-9-6297]         2014               People's Republic of China   Asian                102           59         Gastric cancer                      OS                  SC             NA                 5
  Ozaki et al[@b21-ott-9-6297]       2014               Japan                        Asian                64            71         Hepatocellular Carcinoma            OS                  Reported       109                8
  Lv et al[@b13-ott-9-6297]          2014               People's Republic of China   Asian                114           NA         Gastric cancer                      OS                  Reported       84                 8
  Yu et al[@b24-ott-9-6297]          2013               People's Republic of China   Asian                41            47.3       Nasopharyngeal carcinoma            OS                  Reported       NA                 5
  Roudnicky et al[@b19-ott-9-6297]   2013               Switzerland                  Caucasian            40            NA         Bladder cancer                      RFS                 SC             NA                 4
  Nault1 et al[@b22-ott-9-6297]      2013               France                       Caucasian            58            NA         Early hepatocellular carcinoma      OS/RFS              SC             30                 7
  Nault2 et al[@b22-ott-9-6297]      2013               France                       Caucasian            67            NA         Advanced hepatocellular carcinoma   OS                  Reported       13.6               7
  El Behery et al[@b20-ott-9-6297]   2013               Egypt                        Caucasian            100           50.1       Ovarian cancer                      OS                  Reported       36                 8
  Kim et al[@b16-ott-9-6297]         2012               Korea                        Asian                143           NA         Colon carcinoma                     OS/RFS              Reported       80.7               9
  Liu et al[@b14-ott-9-6297]         2010               People's Republic of China   Asian                159           57.2       Gastric cancer                      OS                  Reported       111                7
  Ji et al[@b17-ott-9-6297]          2010               Korea                        Asian                100           NA         Colorectal cancer                   OS                  Reported       NA                 6
  Maurage et al[@b7-ott-9-6297]      2009               USA                          Caucasian            42            NA         Glioblastomas                       OS                  SC             NA                 5
  Huang et al[@b23-ott-9-6297]       2009               People's Republic of China   Asian                90            51         Hepatocellular carcinoma            OS                  Reported       50                 8

**Abbreviations:** NA, not available; NOS, Newcastle--Ottawa; OS, overall survival; RFS, recurrence-free survival; SC, survival curve.

###### 

HRs and 95% CIs for patient survival (OS) in association with endocan expression in enrolled studies

  Authors                            Publication year   Detecting method   Cutoff value   Case number   HR (95% CI)                                                                    
  ---------------------------------- ------------------ ------------------ -------------- ------------- ------------- ---------------------------------------------------------------- ----------------------------------------------------------------
  Jiang et al[@b15-ott-9-6297]       2015               ELISA              68.4 pg/mL     45            44            4.09 (2.27--10.88) M                                             NA
  Zhao et al[@b14-ott-9-6297]        2014               IHC                1%             64            191           1.719 (1.103--3.028) M                                           NA
  Sun et al[@b12-ott-9-6297]         2014               ELISA              0.826 ng/mL    NA            NA            1.912 (0.991--3.688) U                                           NA
  Ozaki et al[@b21-ott-9-6297]       2014               ELISA              2.20 ng/mL     48            16            2.36 (1.22--5.36) M                                              NA
  Lv et al[@b13-ott-9-6297]          2014               ELISA              84.2 pg/mL     NA            NA            2.493 (1.065--6.021) M                                           NA
  Yu et al[@b24-ott-9-6297]          2013               IHC                10%            21            20            3.140 (1.078--9.142) M                                           NA
  Roudnicky et al[@b19-ott-9-6297]   2013               IHC                Score ≥2       12            28            NA                                                               1.83 (0.70--4.74) U[\*](#tfn3-ott-9-6297){ref-type="table-fn"}
  Nault1 et al[@b22-ott-9-6297]      2013               ELISA              5 ng/mL        23            35            1.74 (0.75--4.04) U[\*](#tfn3-ott-9-6297){ref-type="table-fn"}   2.17 (1.1--4.27) U[\*](#tfn3-ott-9-6297){ref-type="table-fn"}
  Nault2 et al[@b22-ott-9-6297]      2013               ELISA              5 ng/mL        38            29            1.16 (0.48--2.79) M                                              NA
  El Behery et al[@b20-ott-9-6297]   2013               IHC                Score ≥73.5    NA            NA            3.31 (2.10--4.35) M                                              NA
  Kim et al[@b16-ott-9-6297]         2012               IHC                25%            76            67            3.531 (1.632--7.644) M                                           2.109 (1.196--3.716) M
  Liu et al                          2010               IHC                25%            92            67            1.88 (1.15--3.08) M                                              NA
  Ji et al[@b17-ott-9-6297]          2010               ELISA              76 pg/mL       NA            NA            3.394 (1.285--8.963) M                                           NA
  Maurage et al[@b7-ott-9-6297]      2009               ELISA              NA             15            27            1.68 (1.02--2.77) U[\*](#tfn3-ott-9-6297){ref-type="table-fn"}   NA
  Huang et al[@b23-ott-9-6297]       2009               IHC                Score ≥73.5    NA            NA            3.31 (2.10--4.35) M                                              NA

**Notes:** The source of HR and 95% CI is described as derived from univariate analysis (U) or multivariate analysis (M).

HR and 95% CI calculated from survival curves.

**Abbreviations:** CI, confidence intervals; ELISA, enzyme-linked immunosorbent assay; HR, hazard ratio; IHC, immunohistochemistry; NA, not available; OS, overall survival; RFS, recurrence-free survival.

###### 

Main results of meta-analysis

  Categories                   Studies   Patients   HRs    95% CI       Heterogeneity   *P*-value   
  ---------------------------- --------- ---------- ------ ------------ --------------- ----------- ---------
  Overall                      14        1,424      2.48   2.12--2.90   25.80           0.176       \<0.001
  **Cancer type**                                                                                   
  Gastrointestinal carcinoma   7         962        2.27   1.77--2.91   2.00            0.41        \<0.001
  Hepatocellular carcinoma     4         279        2.61   1.96--3.48   48.80           0.119       \<0.001
  Others                       3         183        2.54   1.53--4.20   57.70           0.094       \<0.001
  **Ethnicity**                                                                                     
  Asian                        10        1,157      2.56   2.11--3.11   1.40            0.426       \<0.001
  Caucasian                    4         267        1.99   1.22--3.26   62.90           0.044       0.006
  **Sample type**                                                                                   
  Sera                         8         636        2.08   1.61--2.70   0.00            0.456       \<0.001
  Tissue                       6         788        2.74   2.25--3.34   38.00           0.153       \<0.001
  **Sample size**                                                                                   
  Large                        7         973        2.47   2.00--3.06   19.60           0.28        \<0.001
  Small                        7         451        2.49   1.97--3.14   40.40           0.122       \<0.001
  **Study quality**                                                                                 
  High                         11        1,239      2.63   2.21--3.13   28.40           0.175       \<0.001
  Low                          3         185        1.89   1.30--2.74   0.00            0.582       0.001

**Abbreviations:** CI, confidence interval; HRs, hazard ratios; P~h~, P~Heterogeneity~.
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